Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.67 |
| ▸ | LDHA | P00338 | 2/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 4/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.49 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.49 |
| ▸ | FNTA | P49354 | 1/20 | 0.48 |
| ▸ | FNTB | P49356 | 1/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30877184 | 0.90 | LDHA (0.68) | SLC7A5LDHAESR1MDM2 | |
| SCHEMBL10756180 | 0.87 | SLC7A5 (0.63) | SLC7A5LDHACA2CAMK2AESR1 | |
| SCHEMBL12537008 | 0.84 | SLC7A5 (0.55) | SLC7A5LDHACA2CAMK2AESR1 | |
| SCHEMBL10436391 | 0.84 | CYP1A2 (0.68) | SLC7A5CA2CAMK2AESR1ESR2 | |
| SCHEMBL31179858 | 0.82 | SLC7A5 (0.73) | SLC7A5ESR1ESR2TAAR1SLC6A2 | |
| SCHEMBL7596738 | 0.82 | SLC7A5 (0.53) | SLC7A5LDHACA2CAMK2AESR1 | |
| SCHEMBL2955193 | 0.82 | ESR1 (0.63) | SLC7A5LDHACA2CAMK2AESR1 | |
| SCHEMBL289562 | 0.82 | KDM6B (0.63) | SLC7A5CA2CAMK2AESR1ESR2 | |
| SCHEMBL1067448 | 0.82 | KDM6B (0.63) | SLC7A5CA2CAMK2AESR1ESR2 | |
| SCHEMBL235131 | 0.82 | KDM6B (0.63) | SLC7A5CA2CAMK2AESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117740979-A | Method for establishing fingerprint of pinellia decoction reference sample | 国药集团德众（佛山）药业有限公司 | 2024-03-22 | — | — | CN | claimed |
| CN-115184533-B | LC-MS method for quantitatively detecting golden bell oral liquid | 山东宏济堂制药集团股份有限公司 | 2023-06-20 | — | — | CN | claimed |
| CN-115184533-A | LC-MS method for quantitatively detecting gold scallop oral liquid | 山东宏济堂制药集团股份有限公司 | 2022-10-14 | — | — | CN | claimed |
| WO-2025056330-A1 | STABILIZED POLYMER COMPOSITIONS WITH IMPROVED COLOR RESISTANCE | CYTEC INDUSTRIES INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| CN-118914398-A | Feature map construction method and application of kudzuvine root decoction and preparation thereof | 华润三九现代中药制药有限公司 | 2024-11-08 | — | — | CN | disclosed |
| WO-2024092160-A2 | BIFUNCTIONAL PROTEASES AND USES THEREOF | FLAGSHIP PIONEERING INNOVATIONS VII, LLC (US) | 2024-05-02 | — | — | WO | disclosed |
| CN-117740979-A | Method for establishing fingerprint of pinellia decoction reference sample | 国药集团德众（佛山）药业有限公司 | 2024-03-22 | — | — | CN | disclosed |
| WO-2024052176-A1 | RHEOLOGY MODIFYING OF POLYMERS WITH A RADICAL INITIATOR AND THIOURETHANE | BASF SE (DE) | 2024-03-14 | — | — | WO | disclosed |
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230287365-A1 | COMPOSITIONS AND METHODS FOR DECREASING INFLAMMATION | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230190950-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20080171004-A1 | Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives | MERCK PATENT GMBH (DE) | 2008-07-17 | — | — | US | disclosed |
| US-20080152603-A1 | Antioxidants | SUSONITY Commercial GmbH (DE) | 2008-06-26 | — | — | US | disclosed |
| EP-1871339-A1 | UV PROTECTION | Merck Patent GmbH (DE) | 2008-01-02 | — | — | EP | disclosed |
| CN-1861560-A | Carboxylic acid derivant, its preparation process and pharmaceutical composition | SHANGHAI PHARMACEUTICAL INST C (CN) | 2006-11-15 | — | — | CN | disclosed |
| WO-2006111234-A1 | UV PROTECTION | MERCK PATENT GMBH (DE) | 2006-10-26 | — | — | WO | disclosed |
| US-20030212100-A1 | Quinoline derivatives and medicinal use thereof | MITSUI CHEMICALS, INC. (JP) | 2003-11-13 | — | — | US | disclosed |
| EP-1266888-A1 | QUINOLINE DERIVATIVES AND MEDICINAL USE THEREOF | Mitsui Chemicals, Inc. (JP) | 2002-12-18 | — | — | EP | disclosed |
| EP-0361365-A1 | Aminobenzoic and aminocyclohexane-carboylic acid compounds, compositions, and their method of use | E.R. SQUIBB & SONS, INC. (US) | 1990-04-04 | — | — | EP | disclosed |
| EP-0029803-B1 | ORGANIC POLYMERIC MATERIALS STABILIZED WITH CALCIUM STEAROYL LACTATE | K.K. Musashino Kagaku Kenkyusho (JP) | 1985-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | SLC7A5 2400/4885LDHA 1666/4885CA2 2150/4885 |
| US-20080152603-A1 | Antioxidants | GPX4, GPX1, CAT | SLC7A5 2724/4885LDHA 612/4885CA2 1558/4885 |
| US-20030212100-A1 | Quinoline derivatives and medicinal use thereof | PPARG, PPARD, PPARA | SLC7A5 3794/4885LDHA 2228/4885CA2 4783/4885 |
| US-20080171004-A1 | Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives | HPD, HAAO, UGT1A6 | SLC7A5 497/4885LDHA 843/4885CA2 2547/4885 |
| US-20230190950-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | SLC7A5 2733/4885LDHA 2049/4885CA2 1661/4885 |
| US-20230287365-A1 | COMPOSITIONS AND METHODS FOR DECREASING INFLAMMATION | ENTPD1, ENTPD2, ENTPD5 | SLC7A5 2366/4885LDHA 647/4885CA2 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.